As Real World Data determines drug value, eyeforpharma analyzes the drivers and strategies in the shifting environment – by talking directly to the executives that define them. Here are two exclusive industry case studies, part of eyeforpharma’s complimentary Pharma Insights dossier, available for download here. (Source: eyeforpharma).
- Marc Berger, VP Real World Data and Analytics at Pfizer on their Approach to the Acquisition and Use of Real World Data
- David S. Memel, VP, Health Economics and Outcomes Research at Boehringer Ingelheim on RWE and Strategic Relationships Between Pharma and Organized Customers